Anemia management in cancer patients with chronic kidney disease

Published: 15 September 2016
Author(s): Andras T. Deak, Katharina Troppan, Alexander R. Rosenkranz
Section: Narrative Review

Anemia is a common complication of cancer and chronic kidney disease (CKD) associated with decreased physical performance as well as poor prognosis for life expectancy. Renal and cancer-induced anemia share common features regarding pathogenesis and therapeutic strategies. It is typically treated with iron substitution, erythropoiesis-stimulating agents (ESA) and in refractory cases with red blood cell transfusions. However, studies of the past few years unveiled numerous setbacks in the use of ESAs.